These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

558 related items for PubMed ID: 24168763

  • 1. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.
    Wang S, Huang J, Lyu H, Cai B, Yang X, Li F, Tan J, Edgerton SM, Thor AD, Lee CK, Liu B.
    Breast Cancer Res; 2013; 15(5):R101. PubMed ID: 24168763
    [Abstract] [Full Text] [Related]

  • 2. The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells.
    Huang J, Wang S, Lyu H, Cai B, Yang X, Wang J, Liu B.
    Mol Cancer; 2013 Nov 11; 12(1):134. PubMed ID: 24215614
    [Abstract] [Full Text] [Related]

  • 3. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
    Wang S, Huang X, Lee CK, Liu B.
    Oncogene; 2010 Jul 22; 29(29):4225-36. PubMed ID: 20498641
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H, Huang J, Edgerton SM, Thor AD, He Z, Liu B.
    Int J Clin Exp Pathol; 2015 Jul 22; 8(6):6143-56. PubMed ID: 26261492
    [Abstract] [Full Text] [Related]

  • 7. The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells.
    Lyu H, Yang XH, Edgerton SM, Thor AD, Wu X, He Z, Liu B.
    Oncotarget; 2016 Jan 19; 7(3):2921-35. PubMed ID: 26621843
    [Abstract] [Full Text] [Related]

  • 8. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.
    Liu B, Fan Z, Edgerton SM, Yang X, Lind SE, Thor AD.
    Cell Cycle; 2011 Sep 01; 10(17):2959-66. PubMed ID: 21862872
    [Abstract] [Full Text] [Related]

  • 9. Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.
    Lyu H, Wang S, Huang J, Wang B, He Z, Liu B.
    Cancer Lett; 2018 Apr 28; 420():97-108. PubMed ID: 29409974
    [Abstract] [Full Text] [Related]

  • 10. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z, Paul BT, Craft B, ElShamy WM.
    Breast Cancer Res; 2015 Jan 13; 17(1):5. PubMed ID: 25583261
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
    Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, Hung MC, Yu D.
    Cancer Res; 2002 Oct 15; 62(20):5703-10. PubMed ID: 12384528
    [Abstract] [Full Text] [Related]

  • 13. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells.
    Wang S, Huang J, Lyu H, Lee CK, Tan J, Wang J, Liu B.
    Cell Death Dis; 2013 Mar 21; 4(3):e556. PubMed ID: 23519125
    [Abstract] [Full Text] [Related]

  • 14. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.
    Huang X, Gao L, Wang S, Lee CK, Ordentlich P, Liu B.
    Cancer Res; 2009 Nov 01; 69(21):8403-11. PubMed ID: 19826038
    [Abstract] [Full Text] [Related]

  • 15. In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.
    Shen G, Huang H, Zhang A, Zhao T, Hu S, Cheng L, Liu J, Xiao W, Ling B, Wu Q, Song L, Wei W.
    Cancer Immunol Immunother; 2011 Mar 01; 60(3):339-48. PubMed ID: 21086124
    [Abstract] [Full Text] [Related]

  • 16. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin.
    Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X, Esteva FJ, Liu B.
    Cancer Res; 2010 Feb 01; 70(3):1204-14. PubMed ID: 20103628
    [Abstract] [Full Text] [Related]

  • 17. ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.
    Morrison MM, Hutchinson K, Williams MM, Stanford JC, Balko JM, Young C, Kuba MG, Sánchez V, Williams AJ, Hicks DJ, Arteaga CL, Prat A, Perou CM, Earp HS, Massarweh S, Cook RS.
    J Clin Invest; 2013 Oct 01; 123(10):4329-43. PubMed ID: 23999432
    [Abstract] [Full Text] [Related]

  • 18. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
    Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI.
    Breast Cancer Res; 2007 Oct 01; 9(4):R50. PubMed ID: 17686159
    [Abstract] [Full Text] [Related]

  • 19. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.
    Garrett JT, Sutton CR, Kuba MG, Cook RS, Arteaga CL.
    Clin Cancer Res; 2013 Feb 01; 19(3):610-9. PubMed ID: 23224399
    [Abstract] [Full Text] [Related]

  • 20. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
    García-Parra J, Dalmases A, Morancho B, Arpí O, Menendez S, Sabbaghi M, Zazo S, Chamizo C, Madoz J, Eroles P, Servitja S, Tusquets I, Yelamos J, Lluch A, Arribas J, Rojo F, Rovira A, Albanell J.
    Eur J Cancer; 2014 Oct 01; 50(15):2725-34. PubMed ID: 25128455
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.